Background Insulin resistance is an overlapping risk factor for both heart and breast cancer,
while its interaction with cardiotoxicity in breast cancer (BC) patients is not clear. This study …

Aims An improved understanding of the pathophysiology of trastuzumab-mediated
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …

Background: Trastuzumab improves therapeutic outcomes among patients with human
epidermal growth factor receptor 2–positive breast cancer (BC). However, it is associated …

Background: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (BCA) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …

Background Trastuzumab is life‐extending therapy for breast cancer patients
overexpressing the human epidermal growth factor receptor 2 (HER 2+), but has known …

Background Trastuzumab (TZ) therapy requires careful monitoring of left ventricular (LV)
ejection fraction (LVEF) because it can be potentially cardiotoxic. However, LVEF is an …

To evaluate the cardiac safety of anti-HER2-targeted therapy for early breast cancer; to
investigate whether trastuzumab combined with pertuzumab increases cardiac toxicity …

Purpose Trastuzumab improves survival in patients with HER2+ early breast cancer.
However, cardiotoxicity remains a concern, particularly in the curative setting, and there are …

Background There is limited evidence regarding the impact of cardiology involvement in the
care of cancer patients. Objectives This study evaluated the impact of cardiology …

Background Cardiotoxicity is an adverse effect of trastuzumab (TRA) in the treatment of
human epidermal growth factor 2 positive (HER2+) breast cancer. Current literature on the …